|
2nd International AIDS Society Conference on HIV Pathogenesis and TreatmentParis, France - July 13 - 16, 2003 |
IAS Conf HIV Pathog Treat 2003 Jul 13-16;2nd: Abstract No. 693
Antiviral Therapy 2003; 8(Suppl. 1):S375-S376
[ABSTRACT:] Background: Convenient, non-food dependent dosing, low tablet volume and relatively low cost have made non-nucleoside reverse transcriptase inhibitors a first choice for both clinicians and patients in Uganda. Concerns exist as to their efficacy in patients with viral loads (VL) above 100,000 copies/ml, a feature common to about 75% of HIV-1 infected patients presenting at the Joint Clinical Research Center (JCRC) in Uganda. Furthermore, there is little data on the response to such therapy of non-B subtypes, A and D, predominant in Uganda.
Results: Presented here is a retrospective analysis of therapeutic responses in 11 antiretroviral naïve HIV-1 infected Ugandan patients who had been initiated on Zidovudine (AZT), Lamivudine (3TC) and efavirenz (EFV). Laboratory assessments subsequent to initiation of ARV therapy, done at 11.6 ±3.9 weeks and 30.6 ±5.9 weeks, showed 88.9% and 71.4% patients achieved undetectable viral load respectively. Virological suppression to below detection occurred in 85.7% patients at 11.6 weeks despite baseline VL >100,000 copies/ml. At 31 weeks there was a median increment of +183 cells/mm3 in CD4+ T lymphocytes.
Conclusion: These findings reflect significant efficacy in the use of AZT+3TC+EFV in advanced ARV naïve non-B subtype HIV-1 infected patients. The therapeutic responses were comparable to those previously described in the western world.
030714
693
Copyright © 2003 - International AIDS Society (IAS) and International Medical Press (IMP). Reproduction courtesy of International Medical Press.